Axiom Therapeutics, which develops more precise and potent therapies through cutting-edge computational research, has appointed an Advisor to support the strategic development of its covalent inhibitor pipeline.
The Advisor will guide target selection and help integrate Axiom’s kinact/Ki platform into predictive PK/PD decision-making, strengthening the link between computational insights and drug design.
By introducing best-practice approaches in modern covalent inhibitor discovery, the appointment enhances Axiom’s ability to progress differentiated candidates toward the clinic with greater confidence and efficiency.
